The compounded tirzepatide court ruling leaves FDA's decision to end the national tirzepatide shortage in place. In practical terms, the broad shortage-era route for making copies is closed. The ruling does not erase every narrow, patient-specific form of pharmacy compounding, and it does not decide whether one person's prescription meets federal and state requirements.
A companion ruling reached the same result for semaglutide. So if the worry is, “Does every compounded GLP-1 prescription disappear tomorrow?” the careful answer is no. The shortage argument lost; the separate rules for an identified patient still have to be applied case by case.
What the compounded tirzepatide court ruling decided
As of September 6, 2026, the day this article was written, the Fifth Circuit had affirmed FDA in two cases filed by compounding groups. The tirzepatide opinion, No. 25-10600, was filed August 27. The semaglutide opinion, No. 25-10758, was filed August 27 and revised September 1. Both were per curiam, meaning issued in the panel's name, and unpublished, meaning not designated for publication under the circuit's rule.
The compounders made two main arguments. First, they said FDA should have used notice and comment under the Administrative Procedure Act, the law that sets basic procedures for federal agency decisions. Second, they said FDA's shortage findings were arbitrary or capricious, a legal test asking whether an agency considered the relevant evidence and connected the facts to its decision.
The court did not decide whether skipping notice and comment was an error. It assumed there might have been an error, then found it harmless because the compounders had notice, submitted information, and did not show what they would have added through a formal comment period. It also held that FDA had reasonably weighed manufacturer supply data against pharmacy screenshots, patient reports, and other evidence. The district court judgments for FDA therefore stayed in place.
What the rulings mean now
The clean takeaway is that the national shortage can no longer serve as the broad reason to make copies of Mounjaro, Zepbound, Ozempic, or Wegovy. That was already FDA's position after its transition periods ended in 2025. The panel rejected the appeals that sought to undo those shortage determinations.
The opinions also separate a national shortage from a frustrating local experience. A pharmacy can be out of one strength, an insurer can deny coverage, or a patient can have trouble locating stock without national demand exceeding national supply. The court found that FDA had explained why those individual reports did not outweigh the broader inventory and production record.
A market shift was already visible before the decisions. In a March 9, 2026 announcement, Hims & Hers said it would stop advertising compounded GLP-1 offerings and offer compounded semaglutide only on a limited scale when a provider found it clinically necessary. The announcement did not say all patient-specific compounding had ended.
What the rulings do not mean
They do not turn every patient-specific prescription into a violation. FDA's April 1, 2026 GLP-1 compounding update describes a separate route under section 503A. That is traditional compounding, where a state-licensed pharmacy prepares medication for an identified patient after receiving a prescription.
That route is narrow. FDA says a 503A compounder generally may not make an essentially identical copy regularly or in large amounts. Its policy recognizes an exception when the prescriber determines and documents that a change produces a significant difference for that particular patient. A prescription by itself does not settle the question, and adding another ingredient by itself does not settle it either. Compounded tirzepatide and compounded semaglutide explain those patient-specific rules in detail.
The rulings also did not decide whether either molecule works or whether a particular formulation is right for someone. In SURMOUNT-1, a 2022 trial of 2,539 adults, average weight change at 72 weeks ranged from −15.0% to −20.9% across the three tirzepatide groups, compared with −3.1% on placebo (Jastreboff et al., New England Journal of Medicine). In STEP 1, a 2021 trial of 1,961 adults, the average change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo (Wilding et al., New England Journal of Medicine). Those numbers belong to the products and protocols studied, not to every compounded formulation.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor. Nothing in these opinions decides whether a particular Promise prescription or pharmacy preparation meets every applicable requirement.
What to watch next: the 503B decision
Section 503B covers outsourcing facilities, larger compounding operations that can supply office stock without a prescription for each named patient and must meet added federal requirements. Their path is separate from 503A. FDA's April update says semaglutide and tirzepatide are on neither the shortage list nor the 503B bulks list.
On May 1, 2026, FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list. A June 26 Federal Register notice extended comments through July 30. No final determination appeared in the Federal Register through September 6. That final decision—not these two court opinions—is the next formal event to watch for 503B bulk compounding.
Where this leaves a patient
The court decisions settle the shortage fight, not an individual's care. A legitimate route should identify the prescriber, the dispensing pharmacy, and the patient-specific reason for a compounded preparation. How compounded medications are made shows what that accountable chain looks like.
At Promise, a licensed provider reviews every request and not everyone qualifies. The useful question is no longer whether the old shortage created a broad opening. It is whether the clinician and pharmacy can explain why this exact prescription fits the narrower rules now in force.